Skip to main content
Premium Trial:

Request an Annual Quote

NCI Awards $13.4 Million for Cancer Biomarker Discovery

NEW YORK, Dec. 8 (GenomeWeb News) - The National Cancer Institute has awarded two research teams $13.4 million to develop standard tools and resources needed to accelerate cancer protein biomarker discovery.


The two-year awards were made by NCI's operations and technical support contractor, Science Applications International Corp.-Frederick. Samir Hanash, of the University of Michigan, and Martin McIntosh and Amanda Paulovich, of the FredHutchinsonCancerResearchCenter, will lead the two teams, which include researchers from 10 cancer research institutions.


The researchers will use transgenic mouse models of human cancers to study current proteomic technologies, compare results, and provide reference data sets and biological resources for widespread research use, NCI said. According to the institute, once complete, the project will yield the first reliable and broad-based technological platform for the discovery and clinical validation of protein biomarkers for cancer.


Data and information from the project will be integrated and distributed through the Biomedical Informatics Grid.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.